XML 48 R38.htm IDEA: XBRL DOCUMENT v3.26.1

Loss Per Share (Tables)

6 Months Ended

Dec. 31, 2025

Loss Per Share [Abstract]

Schedule of Loss Per Share

		Consolidated				Consolidated
		December 2025 $				December 2024 $
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(12,552,490	)			(10,453,811	)

		Number				Number
Weighted average number of ordinary shares used in calculating basic loss per share			1,560,213,259				425,157,427
Weighted average number of ordinary shares used in calculating diluted loss per share			1,560,213,259				425,157,427

		Cents				Cents
Basic loss per share			(0.805	)			(2.459	)
Diluted loss per share			(0.805	)			(2.459	)

X

- References

No definition available.

+ Details

Name:	ifrs-full_EarningsPerShareAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2025-01-01
-Paragraph 66
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_EarningsPerShareExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration